524632 Stock Overview
Develops, manufactures, markets, and exports various drugs and dosage forms in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Shukra Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹129.88 |
| 52 Week High | ₹129.90 |
| 52 Week Low | ₹30.33 |
| Beta | 0.24 |
| 1 Month Change | 112.12% |
| 3 Month Change | 74.66% |
| 1 Year Change | 328.29% |
| 3 Year Change | 511.56% |
| 5 Year Change | 878.38% |
| Change since IPO | 233.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524632 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 21.5% | 1.7% | 0.2% |
| 1Y | 328.3% | 39.1% | 17.2% |
Return vs Industry: 524632 exceeded the Indian Pharmaceuticals industry which returned 39.1% over the past year.
Return vs Market: 524632 exceeded the Indian Market which returned 17.2% over the past year.
Price Volatility
| 524632 volatility | |
|---|---|
| 524632 Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: 524632's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 524632's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 182 | Dakshesh Shah | www.shukrapharmaceuticals.com |
Shukra Pharmaceuticals Limited develops, manufactures, markets, and exports various drugs and dosage forms in India and internationally. Its product portfolio includes macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti tuberculosis, vitamin products, anti allergics, corticosteroids, hyper and hypoglycemic, and other products, as well as antibiotics, such as penicillin and cephalosporin. The company was formerly known as Relish Pharmaceuticals Limited and changed its name to Shukra Pharmaceuticals Limited in August 2016.
Shukra Pharmaceuticals Limited Fundamentals Summary
| 524632 fundamental statistics | |
|---|---|
| Market cap | ₹5.42b |
| Earnings (TTM) | ₹144.32m |
| Revenue (TTM) | ₹412.59m |
39.4x
P/E Ratio13.8x
P/S RatioIs 524632 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524632 income statement (TTM) | |
|---|---|
| Revenue | ₹412.59m |
| Cost of Revenue | ₹113.41m |
| Gross Profit | ₹299.18m |
| Other Expenses | ₹154.86m |
| Earnings | ₹144.32m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.30 |
| Gross Margin | 72.51% |
| Net Profit Margin | 34.98% |
| Debt/Equity Ratio | 5.0% |
How did 524632 perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield24%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 16:35 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shukra Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|